跳至主要内容
临床试验/NCT00446056
NCT00446056已完成4 期

Montelukast, on Pediatric Bronchial Asthma in Multicenter Comparative Double-Blind Clinical Study (Phase IV) With Ketotifen Fumarate

Organon and Co0 个研究点目标入组 188 人开始时间: 2003年9月25日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
188
主要终点
Improvement of morning peak expiratory flow over first 2 weeks

研究概览

简要总结

The clinical study evaluates the safety of montelukast and compares montelukast to ketotifen, used as a control drug, in terms of improvement in morning peak expiratory flow (am pef) over first 2 weeks in patients with pediatric bronchial asthma aged 6 to < 15.

The effect of body weight on the efficacy and safety of montelukast will also be evaluated in this study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
6 Years 至 14 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Intermittent asthma, mild persistent asthma, moderate persistent asthma, or severe persistent asthma patients with 2 or more mild or moderate attacks at baseline

排除标准

  • Patient using anti-asthma treatment or therapy including corticosteroids or oral anti-allergic drugs
  • Patient with complications that will impair the judgment of efficacy of this drug
  • Patient with convulsive disorders such as epilepsy or such a history
  • Patient with liver disease, renal impairment, heart disease or such other complication

结局指标

主要结局

Improvement of morning peak expiratory flow over first 2 weeks

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验